CUTISS Innovation, our French subsidiary, was honored to win the ‘Innovation’ trophy for continued innovation and research into regenerative medicine and skin pigmentation. This was part of the first annual Impact Awards, a jury-led competition organized by Team Côte d’Azur that recognizes leading companies of the local economic ecosystem. Our director Cécile Cousin was there […]
CUTISS Innovation wins Impact Award 2022 Read More »
CUTISS won 4th place in this year’s jury-led TOP100 Swiss Startup Award, hosted by Venturelab. CUTISS won 1st in 2020 and 2nd place in 2021. In the Biotech sub-category, we continue to place 1st for the fourth years in a row now. We are proud of our team and thank you to the jury for their
CUTISS reaches 4th place at TOP100 Swiss Startup Award Read More »
PRESS RELEASE CUTISS completes recruitment for denovoSkin™ Phase 2 clinical trial in adult and adolescent burn patients Switzerland, 7 September 2022 – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced the completion of recruitment for the Phase 2 clinical trial of its lead product denovoSkin™
Recruitment completed for denovoSkin Phase 2 clinical trial, adult & adolescent patients Read More »
As part of the 25th anniversary celebrations of >>venture>>, Daniela contributed an opinion piece on how we can better nurture startups in Switzerland. Newsroom article le matin dimanche (French)
Le Matin Dimanche opinion article Read More »
CUTISS is pleased to announce that a tissue graft patent has been granted by the European Patent Office for the personalized bioengineered human skin tissue therapy developed by CUTISS. The patent (3174563) has been granted pursuant to Article 97(1) EPC to University of Zurich (UZH) where the founders of CUTISS worked at the time of
CUTISS granted European patent for skin tissue graft Read More »
The Swiss daily business newspaper Agefi published an interview with our CEO Daniela Marino following the announcement that CUTISS started onsite denovoSkin production, at its very own GMP facility. This is an exciting milestone for the company, resulting in greater production flexibility and scale-up opportunities. Newsroom Link to Interview
Agefi reports on the start of on-site production Read More »
CUTISS achieves full independence in its manufacturing capabilities with onsite facility. Increased agility and capacity in producing denovoSkin for current and future clinical trials and patients on compassionate basis. Successful transfer of technology and departure from Wyss Zurich Translational Center, a joint accelerator created by Hansjörg Wyss together with the University of Zurich and ETH
The popular French science magazine Sciences et Avenir has published an article explaining the science behind our denovoSkin and denovoCast innovations, and the promise that this brings to patients suffering from severe skin burns and injuries. The journalist had visited CUTISS to see this for herself and to speak with our CEO Daniela and CIO Vincent. “Swiss
Sciences et Avenir: A machine produces personalized skin Read More »
PRESS RELEASE Two innovative biotechnology specialists, IBSA Pharma and CUTISS complete license agreement for VitiCell® Agreement grants CUTISS exclusive worldwide license to commercialize VitiCell®. VitiCell® is a CE marked medical device developed by IBSA for the treatment of skin pigmentation disorders. Strategic fit with CUTISS’s expertise in skin tissue bioengineering. Sophia-Antipolis (France) and Zurich (Switzerland), 2
IBSA Pharma and CUTISS complete license agreement for VitiCell Read More »
CUTISS opens subsidiary in France and secures first government grant to extend its Research and Development in regenerative medicine The subsidiary CUTISS Innovation, based at Sophia Antipolis, Europe’s leading technology park, will focus on R&D and innovation in regenerative medicine. A grant of EUR 300,000 from the Region Provence-Alpes-Cote d’Azur will contribute towards the installation
CUTISS opens R&D subsidiary in France and secures first grant Read More »
CUTISS AG
CUTISS HAUS
Grabenstrasse 11
8952 Schlieren, Switzerland
info@cutiss.swiss
Tel. +41 44 244 36 60
© Cutiss AG. All rights reserved.
Would you like to contact us as a journalist?
